跳至主要内容
临床试验/NCT00848289
NCT00848289
进行中(未招募)
不适用

Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach

M.D. Anderson Cancer Center2 个研究点 分布在 1 个国家目标入组 6,086 人1998年2月10日
干预措施Interviews

概览

阶段
不适用
干预措施
Interviews
疾病 / 适应症
Bladder Cancer
发起方
M.D. Anderson Cancer Center
入组人数
6086
试验地点
2
主要终点
Comparison of mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen
状态
进行中(未招募)
最后更新
3个月前

概览

简要总结

This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

详细描述

Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

注册库
clinicaltrials.gov
开始日期
1998年2月10日
结束日期
2026年8月1日
最后更新
3个月前
研究类型
Observational
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Subject has a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer
  • Subject is a Texas resident.
  • Subject can understand English or a qualified translator is available for the interview.
  • Subjects of any age, gender, or ethnicity are eligible to participate in the study.
  • Subject consents to participate in the study.

排除标准

  • Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past 6 months.
  • Subject has been diagnosed with superficial or muscle-invasive bladder cancer more than twelve months ago.

研究组 & 干预措施

Participants with Bladder Cancer

Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.

干预措施: Interviews

结局指标

主要结局

Comparison of mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen

时间窗: After last subject has completed the study, up to 5 years

Mutagen sensitivity as measured by quantifying the number of lymphocytic chromatid breaks and comet tail moments induced by in vitro exposure to bleomycin (a radiomimetic agent) and benzo\[a\]pyrene diol epoxide (BPDE, a tobacco carcinogen) in bladder cancer cases in comparison to data for controls

次要结局

  • Associations between the cytogenetic, molecular components and epidemiologic covariates (age, sex, ethnicity, cigarette smoking status, alcohol use, dietary intake, and family history of cancer) in risk of bladder cancer(After the last subject has completed the study, up to 5 years per individual participation)
  • Frequencies of polymorphisms in those genes that regulate the metabolism of carcinogens in tobacco smoke(After the last subject completes the study, up to 5 years)

研究点 (2)

Loading locations...

相似试验